Original Article(s)
13 February 2025
Vol. 13 (2025)
Medication adherence in patients with carotid artery stenosis before/after enrollment in CARUSO study
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
387
Views
127
Downloads
Authors
Background: this work analyses the medical therapy adherence of patients enrolled in a clinical study. The primary end- point of this research is to find out if enrolment in a clinical study can improve adherence to antiplatelet and/or lipid- lowering therapy.
Materials and Methods: the first 92 asymptomatic patients with carotid artery stenosis ≥50% enrolled in the CARUSO study were considered. Overall baseline “compliance” to anti-platelet treatment was stratified in patients with good, average, and poor adherence.
Results: overall compliance with anti-platelet therapy was good for 66 patients (95.7%) out of 69 patients already under this treatment. A significant correlation between good adherence to pharmacological therapy and the presence of previ- ous cardiovascular events at the time of enrolment: 92.3% (one event), 84.6% (two events), 50% (three events) vs 35.1% of those without events (p<0.001). After 6 months, good adherence was found to extend even to patients with no previ- ous events (p=0.083).
Conclusions: this research showed a positive trend in improving adherence to lipid-lowering therapy (88.3% vs 56.7%, p=0.002) and maintenance of a high level (> 95%) of adherence to anti-platelet therapy, after the enrolment in a clinical study.
Altmetrics
Downloads
Download data is not yet available.
Citations
Società Italiana di Chirurgia Vascolare ed Endovascolare (SICVE). Linea guida: diagnosi e trattamento della patologia steno ostruttiva carotidea extracranica e prevenzione dell'ictus cerebrale. 2021. Available from: https://sicve.it/wp-content/uploads/2022/05/Linea-Guida-261-patologia-carotidea-CNEC.pdf
Cutrona SL, Choudhry NK, Fischer MA, et al. Targeting cardiovascular medication adherence interventions. J Am Pharm Assoc. 2012;52:381-97. DOI: https://doi.org/10.1331/JAPhA.2012.10211
Gomez Sandoval YH, Braganza MV, Daskalopoulou SS. Statin discontinuation in high-risk patients: a systematic review of the evidence. Curr Pharm Des. 2011;17:3669-89. DOI: https://doi.org/10.2174/138161211798220891
Mann DM, Woodward M, Muntner P, et al. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44:1410-21. DOI: https://doi.org/10.1345/aph.1P150
National Cholesterol Education Program (NCEP). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143-421. DOI: https://doi.org/10.1161/circ.106.25.3143
Brookhart MA, Patrick AR, Schneeweiss S, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007;167:847-52. DOI: https://doi.org/10.1001/archinte.167.8.847
Aubert RE, Yao J, Xia F, Garavaglia SB. Is there a relationship between early statin compliance and a reduction in healthcare utilization? Am J Manag Care. 2010;16:459-66.
Shroufi A, Powles JW. Adherence and chemoprevention in major cardiovascular disease: a simulation study of the benefits of additional use of statins. J Epidemiol Community Health. 2010;64:109-13. DOI: https://doi.org/10.1136/jech.2009.091033
Krist AH, Davidson KW, Mangione CM, et al. Behavioral counseling interventions to promote a healthy diet and physical activity for cardiovascular disease prevention in adults with cardiovascular risk factors: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;324:2069-75. DOI: https://doi.org/10.1001/jama.2020.21749
Giannopoulos A, Kakkos S, Abbott A, et al. Long-term mortality in patients with asymptomatic carotid stenosis: implications for statin therapy. Eur J Vasc Endovasc Surg. 2015;50:573e82. DOI: https://doi.org/10.1016/j.ejvs.2015.06.115
Naylor AR, Ricco J-B, De Borst GJ, et al. Editor's Choice - Management of Atherosclerotic Carotid and Vertebral Artery Disease: 2017 Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2018;55:3-81. DOI: https://doi.org/10.1016/j.ejvs.2018.03.023
Aranzulla TC, Piazza S, Ricotti A, et al. Carotid plaque stabilization and regression with evolocumab: rationale and design of the CARUSO study. Catheter Cariovasc Interv. 2021;1;98:E115-21. DOI: https://doi.org/10.1002/ccd.29743
Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med. 2010;7:e1000251. DOI: https://doi.org/10.1371/journal.pmed.1000251
Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-97. DOI: https://doi.org/10.1056/NEJMra050100
Brown MT, Bussell JK. Medication adherence: WHO cares? Mayo Clin Proc. 2011;86:304-14. DOI: https://doi.org/10.4065/mcp.2010.0575
Adams JR, Elwyn G, Legare F, Frosch DL. Communicating with physicians about medical decisions: a reluctance to disagree. Arch Intern Med. 2012;172:1184-6. DOI: https://doi.org/10.1001/archinternmed.2012.2360
Doshi JA, Zhu J, Lee BY, et al. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation. 2009;119:390-7. DOI: https://doi.org/10.1161/CIRCULATIONAHA.108.783944
Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med. 2011;171:814-22. DOI: https://doi.org/10.1001/archinternmed.2010.495
Schedlbauer A, Davies P, Fahey T. Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev. 2010;3:CD004371. DOI: https://doi.org/10.1002/14651858.CD004371.pub3
Nieuwkerk PT, Nierman MC, Vissers MN, et al. Intervention to improve adherence to lipid-lowering medication and lipid-levels in patients with an increased cardiovascular risk. Am J Cardiol. 2012;110:666-72. DOI: https://doi.org/10.1016/j.amjcard.2012.04.045
Gaw A, Tolmie E, Lindsay GM. The statin breakthrough—remembering to involve the patient. Cardiovasc Drugs Ther. 2004;18:343-4. DOI: https://doi.org/10.1007/s10557-005-5057-9
Yilmaz MB, Pinar M, Naharci I, et al. Being well-informed about statin is associated with continuous adherence and reaching targets. Cardiovasc Drugs Ther. 2005;19:437-40. DOI: https://doi.org/10.1007/s10557-005-5202-5
O’Malley PG. On motivating patients: a picture, even if worth a thousand words, is not enough. Arch Intern Med. 2012;172:309-10. DOI: https://doi.org/10.1001/archinternmed.2011.1948
Golomb BA, McGraw JJ, Evans MA, Dimsdale JE. Physician response to patient reports of adverse drug effects: implications for patient-targeted adverse effect surveillance. Drug Saf. 2007;30:669-75. DOI: https://doi.org/10.2165/00002018-200730080-00003
Golomb BA, Yang E, Denenberg J, Criqui MH. Statin-associated adverse effects. Circulation. 2003;107:e7028-9.
How to Cite
Medication adherence in patients with carotid artery stenosis before/after enrollment in CARUSO study. (2025). Working Paper of Public Health, 13. https://doi.org/10.4081/wpph.2025.10073
Copyright (c) 2025 Michela Lanza, Tiziana Aranzulla, Antonella Cassinari, Giuseppe Musumeci, Andrea Gaggiano, Marianna Farotto, Carlotta Bertolina, Marinella Bertolotti, Antonio Maconi, Alberto Guagliano
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
